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Abstract 
Background: Since 2004, artemisinin-based combination therapy (ACT) has been the first-line treatment for uncom-
plicated malaria in Benin. In 2016, a medicine outlet survey was implemented to investigate the availability, price, and 
market share of anti-malarial treatment and malaria diagnostics. Results provide a timely and important benchmark to 
measure future interventions aimed at increasing access to quality malaria case management services.
Methods: Between July 5th to August 6th 2016, a cross sectional, nationally-representative malaria outlet survey was 
conducted in Benin. A census of all public and private outlets with potential to distribute malaria testing and/or treat-
ment was implemented among 30 clusters (arrondissements). Outlets were eligible for inclusion in the study if they 
met at least one of three study criteria: (1) one or more anti-malarials reportedly in stock on the day of the survey; (2) 
one or more anti-malarials reportedly in stock within the 3 months preceding the survey; and/or (3) provided malaria 
blood testing. An audit was completed for all anti-malarials, malaria rapid diagnostic tests (RDT) and microscopy.
Results: 7260 outlets with the potential to sell or distribute anti-malarials were included in the census and 2966 were 
eligible and interviewed. A total of 17,669 anti-malarial and 494 RDT products were audited. Quality-assured ACT was 
available in 95.0% of all screened public health facilities and 59.4% of community health workers (CHW), and avail-
ability of malaria blood testing was 94.7 and 68.4% respectively. Sulfadoxine–pyrimethamine (SP) was available in 
73.9% of public health facilities and not found among CHWs. Among private-sector outlets stocking at least one anti-
malarial, non-artemisinin therapies were most commonly available (94.0% of outlets) as compared to quality-assured 
ACT (36.1%). 31.3% of the ACTs were marked with a “green leaf” logo, suggesting leakage of a co-paid ACT into Benin’s 
unsubsidized ACT market from another country. 78.5% of the anti-malarials distributed were through the private 
sector, typically through general retailers (47.6% of all anti-malarial distribution). ACT comprised 44% of the private 
anti-malarial market share. Private-sector price of quality-assured ACT ($1.35) was three times more expensive than 
SP ($0.42) or chloroquine ($0.41). Non-artemisinin therapies were cited as the most effective treatment for uncompli-
cated malaria among general retailers and itinerant drug vendors.
Conclusions: The ACTwatch data has shown the importance of the private sector in terms of access to malaria treat-
ment for the majority of the population in Benin. These findings highlight the need for increased engagement with 
the private sector to improve malaria case management and an immediate need for a national ACT subsidy.
Keywords: Benin, Malaria case management, Private sector, Public sector, Artemisinin-based combination therapy, 
Diagnostic test, ACT subsidy
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Background
In Benin, important gains in malaria control have been 
achieved in recent years, however, malaria remains a lead-
ing cause of morbidity and mortality. In 2015, the World 
Health Organization (WHO) reported over two million 
confirmed malaria cases and 1416 deaths in the coun-
try [1]. Malaria is cited as the leading reason for medical 
consultations and hospitalization in Benin [2]. According 
to population based surveys, only 28% of children under 5 
received the first-line treatment for uncomplicated malaria 
[3] and among pregnant women, only one in four were 
found to use intermittent treatment as prevention during 
pregnancy (IPTp) [4]. The financial impact of malaria is 
also of concern in Benin. It is estimated that households 
spend approximately one-quarter of their annual income 
on the prevention and treatment of malaria, meanwhile, 
37% of the Benin population live below the poverty line, 
with a per capita annual income of only $750 [5].
In 2004, the policy for malaria management in Benin 
changed when the National Malaria Control Programme 
(NMCP) introduced artemisinin-based combination ther-
apy (ACT), artemether–lumefantrine (AL), for treatment 
of uncomplicated malaria [1]. Up to that time, chloroquine 
had been used for first-line therapy against uncomplicated 
malaria. In 2011, the guidelines changed and stipulated that 
patients of all ages should receive a confirmatory malaria 
test prior to treatment. In 2014, updates to national policy 
brought malaria to case management guidelines further in-
line with WHO recommendations and stipulated three doses 
of sulfadoxine–pyrimethamine (SP) for IPTp. The NMCP 
also updated the malarial  national case management guide-
lines to align with the WHO recommendation for treatment 
of severe malaria with injectable artesunate and injectable 
artemether [6], though injectable quinine is also still recom-
mended followed by a seven day treatment with oral quinine. 
Treatment for severe malaria should only be administered at 
a public or private hospital. Oral artemisinin monotherapies 
have been banned in Benin since 2008 [1].
As a means to promote universal coverage of first-line 
treatment and increase rates of confirmatory testing, the 
NMCP took significant steps to improve malaria case 
management services across the country. In 2011, public-
sector initiatives included free malaria case management 
to children under 5  years of age and pregnant women. 
Prior to this, public health facilities had charged fees for 
consultation, medications, and procedures [7]. The 2014–
2018 National Malaria Strategic Plan was also developed 
and set the goal that by 2030, “…malaria would no longer 
be a public health problem in Benin” [6]. The strategy 
aims to decrease the number of annual cases by 75% and 
reduce the mortality rate to 1 death per 100,000 people.
There has been a substantial increase in the procure-
ment of ACT and malaria rapid diagnostic tests (RDT) 
as a means to increase universal access to malaria com-
modities. In 2014, over 1.3 million RDT were procured 
and in 2015, this increased to almost 1.5 million [1]. A 
similar pattern followed for the procurement of ACT, 
which increased from 1.1 million in 2014 to 1.2 million 
in 2015. Commodities such as ACT and RDT have largely 
been made available through the public-sector channels.
Other initiatives to improve malaria case management 
services include expanding access to primary health care 
services through the training and equipping of community 
health workers (CHW), including training on the appro-
priate use of RDT as well as the management of malaria, 
pneumonia, diarrhoea, and malnutrition [6]. In 2014, it was 
estimated that over 12,500 CHW were active in the coun-
try. Other public-sector initiatives have included funds for 
the provision of free healthcare to the extremely poor, and 
the reinforcement of health financing schemes [8].
There have been no major initiatives targeting the 
private sector in Benin to improve malaria case man-
agement services, despite evidence that over 70% of anti-
malarials are distributed through this channel [9]. While 
the national strategy has included the provision of diag-
nosis, microscopy or RDT, and ACT in selected private 
health clinics [10], the scale-up is largely in process and 
has yet to be routinely implemented [6]. Indeed, the pri-
vate sector in Benin is renowned for being diverse and 
continuously expanding, with most providers operating 
informally without a license, mainly because the accredi-
tation process is often perceived as difficult and convey-
ing few benefits [6, 11]. While there is a push to simplify 
the process by bringing more of the private sector into 
the formal market, this has yet to be widely implemented.
This lack of private-sector engagement contrasts with 
several other countries that have benefitted from ACT 
subsidies aimed to increase access to first-line treatment 
in the private sector. The most notable of these initiatives 
was the Affordable Medicines Facility-malaria (AMFm), 
which continued through 2016 [12, 13] and was imple-
mented in neighbouring Nigeria, as well as seven other 
countries (Cambodia, Ghana, Kenya, Madagascar, Niger, 
Uganda, and Tanzania). Through this mechanism, sub-
sidized ACT was available on the market and labelled 
with a ‘green leaf ’ logo to indicate quality-assurance. By 
increasing quality-assured ACT on the anti-malarial 
market, the AMFm also aimed to decrease the use of oral 
artemisinin monotherapies, and non-artemisinin mono-
therapies, such as chloroquine. Following the AMFm 
pilot period, the Global Fund continued to support a 
quality-assured ACT subsidy programme through the 
Private Sector Co-payment Mechanism (CPM) [14], but 
Benin was not part of this initiative.
Investigating the anti-malarial and diagnostic mar-
ket landscape will provide an important benchmark to 
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measure future interventions aimed at increasing access to 
quality malaria case management services. However, there 
is limited rigorous evidence on the availability and distri-
bution of anti-malarials and malaria diagnostics in Benin. 
Since 2008, the multi-country ACTwatch project has been 
implemented in Benin to fill contemporary evidence gaps 
by collecting malaria case management commodity mar-
ket data on anti-malarial medicines, malaria diagnostics, 
market share, and price in both the private and public sec-
tors [15]. The objective of this paper is to provide practical 
evidence to inform strategies and policies in Benin towards 
achieving national malaria control goals, by describing the 
total market for malaria medicines and diagnostics at the 
national level according to the most recent survey round. 
Evidence will point to recommendations for improving 
coverage of appropriate malaria case management.
Methods
This was the fourth outlet survey implemented in Benin, 
with previous surveys conducted in 2009, 2011, and 2014 
[16–18]. This study used a cross-sectional, multi-staged 
cluster sampling approach and was stratified according to 
urban/rural areas. The outlet survey followed the design 
implemented in previous survey rounds and across other 
ACTwatch countries. The outlet survey was implemented 
from July 5th to August 6th 2016.
Sampling approach
According to the ACTwatch methodology, outlets are 
included in the survey if they have the ‘potential’ to sell or 
distribute anti-malarials. This includes outlets that may 
not be expected to stock anti-malarial medicines. For 
example, while public health facilities would be expected 
to have anti-malarials in stock, the extent to which gen-
eral retailers or itinerant drug vendors have anti-malar-
ials available may be more debatable. To assess this, the 
ACTwatch study approach is to include all outlets that 
could ‘potentially stock’ anti-malarials.
Outlets sampled in Benin’s public sector included 
public health facilities (including the national referral 
hospital, regional hospitals, district hospitals, health 
centers and dispensaries); CHW and private not-for-
profit facilities (including non-governmental organisa-
tions, hospitals and clinics, and faith-based hospitals 
and clinics). The private-sector outlet types sampled 
were private for-profit health facilities (including pri-
vate hospitals, clinics and diagnostic laboratories); phar-
macies (which are registered and licensed by a national 
regulatory authority); drug stores (Depôts pharmaceu-
tiques); general retailers (grocery stores, kiosks and 
market stalls selling fast-moving consumer products); 
and itinerant drug vendors (mobile, unregistered pro-
viders selling medicines).
The primary sampling approach taken for ACTwatch 
outlet surveys entails sampling a set of administrative 
units (geographic clusters) with a population of approxi-
mately 10,000–15,000 inhabitants. The most appropri-
ate administrative unit in Benin matching the desired 
population size was an ‘arrondissement’. A representative 
sample of arrondissements was selected using probabil-
ity proportional to population size sampling, using data 
from Benin’s fourth Population and Housing census.
As public health facilities, pharmacies, and drug 
shops (dépôts pharmaceutiques) are important provid-
ers of anti-malarials but are relatively uncommon, over-
sampling was conducted for these outlet types in Benin. 
This ‘booster’ sample was obtained by including all pub-
lic health facilities, pharmacies, and drug shops (dépôts 
pharmaceutiques) located in the larger administrative 
area (called a ‘commune’ in Benin) from which a given 
arrondissement was selected. In this instance, the booster 
sample covered all public health facilities, pharmacies, 
and drug shops in the whole commune within which the 
arrondissements were located.
The sample was stratified by urban–rural ward desig-
nation. In total, 15 arrondissement were selected for the 
main census sample (15 rural, 15 urban). Within each 
selected arrondissement a census of all outlet types with 
the potential to provide anti-malarials or diagnostics to 
consumers was undertaken.
Eligibility criteria
Outlets were eligible for a provider interview and malaria 
product audit if they met at least one of three study cri-
teria: (1) one or more anti-malarials reportedly in stock 
on the day of the survey; (2) one or more anti-malarials 
reportedly in stock within the three months preceding the 
survey; and/or (3) provided malaria blood testing (micros-
copy or RDT). Among eligible outlets, providers were 
interviewed and all anti-malarials and RDTs were audited.
Sample size
A series of calculations was completed to identify minimum 
sample size requirements to detect an increase or decrease 
in the availability of quality-assured ACT and of malaria 
blood testing between 2014 and 2016. Calculations exam-
ined the sample size required to detect a 20% point change 
among all outlets, the public sector, the private sector, public 
health facilities, pharmacies, and general retail outlets.
The required sample size for each research domain 
(urban and rural areas) was calculated in three steps: (1) 
determine the required number of anti-malarial-stocking 
outlets, (2) determine the number of outlets to be enu-
merated to arrive at this number of anti-malarial-stocking 
outlets, and (3) determine the number of arrondissement 
for the census to arrive at this number of outlets.
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Required number of anti‑malarial stocking outlets
The number of anti-malarial-stocking outlets required to 
detect a change over time is given by:
where n =  desired sample size,  P1 =  the proportion of 
anti-malarial-stocking outlets with quality-assured ACT/
malaria blood testing available in stock in 2014,  P2 = the 
expected proportion of anti-malarial-stocking outlets 
with quality-assured ACT/malaria blood testing avail-
able in stock in 2016 (20% point increase or decrease), 
P  =  (P1  +  P2)/2,  Zα  =  the standard normal deviation 
value for an α type I error (two-sided),  Z1 − β = the stand-
ard normal deviation value for a βtype II error, Deff = the 
design effect in case of multi-stage arrondissement sam-
ple design. Deff figures from the 2014 dataset were used 
in sample size calculations.
Required number of outlets
The estimated number of outlets enumerated needed for 
the quality-assured ACT availability indicator was deter-
mined by the following formula for outlets within urban 
and rural domains: 
where  Pam is the proportion of outlets having anti-
malarial stocks at the time of the survey among all out-
lets enumerated. In this equation, the assumptions are as 
follows: N = desired sample size of all outlets for moni-
toring availability indicators, n is the number of outlets 
with anti-malarial stocks at the time of the survey.  Pam is 
the proportion of outlets having anti-malarials in stock at 
the time of the survey among outlets enumerated in 2014 
within urban and rural areas. The  Pam values documented 
in the 2014 ACTwatch outlet survey were used for 2016 
sample size calculations.
Required number of arrondissements
The average numbers of outlets by outlet type in arron-
dissements within urban and rural areas screened dur-
ing the 2014 outlet survey were used to estimate the 
number of arrondissements required in 2016 to achieve 
the desired sample sizes. Considering sample size 
requirements to detect change over time and average 
numbers of outlets across each outlet type, the opti-
mal minimum number of localities required to reach 
desired numbers of outlets was 30 arrondissements (15 
urban, 15 rural) plus a booster sample of public health 














The outlet survey census involved systematically looking 
for outlets in each arrondissement and using screening 
questions to identify outlets for inclusion in the study. Pro-
vider interviews and anti-malarial audits were conducted in 
all eligible outlets, after informed consent procedures. Up 
to three call-back visits were made to outlets in instances 
where outlets were closed or providers were not available.
Data were collected using Android phones, except 
in pharmacies that had a large number of anti-malarial 
products. In these pharmacies, paper questionnaires 
were used so that multiple interviewers could audit anti-
malarial products simultaneously to shorten the time 
required to finish the interview. The electronic data 
collection program was developed using DroidDB (© 
SYWARE, Inc., Cambridge, MA, USA).
Measures
Anti-malarial audit information recorded information 
on the formulation, package size, brand name, active 
ingredients and strength(s), manufacturer, country of 
manufacture, reported sale/distribution in the week pre-
ceding the survey, retail price, and wholesale price. The 
RDT audit information collected similar data. In addition 
to the product audit, a series of questions were adminis-
tered to the senior-most provider regarding malaria case 
management knowledge and practices as well as provider 
training and qualifications.
Training
Standard ACTwatch tools and training materials were 
used. A training of trainers was conducted in June 2016 and 
was followed by a pilot test to evaluate the electronic data 
collection program. Interviewers, supervisors, and quality 
controllers then received a training that included an ori-
entation to the study, questionnaire overview, including a 
focus on how to complete the anti-malarial and RDT audits 
and how to use the electronic data collection program.
After the training, a field exercise was conducted out-
side of the selected arrondissements to provide prac-
tical experience for the trainees and to evaluate their 
performance. Supervisors and quality controllers were 
then chosen from the highest performers in the group, 
and these candidates then participated in an additional 
three-day training before the start of data collection. 
Eight teams were formed, each composed of one super-
visor, one quality controller, and five or six interviewers. 
Representatives from the research agency, Association 
Beninoise pour le Marketing Social (ABMS), and the 
ACTwatch central team provided additional supervision 
and support to the data collection teams in the field for 
the entirety of the data collection.
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Data analysis
Data collected with paper questionnaires were double 
entered and verified using a Microsoft Access database. 
All data cleaning and analysis was completed using Stata 
13.1 (©StataCorp, College Station, TX). Sampling weights 
were applied to account for variations in the probabil-
ity of selection and standard error estimation accounted 
for clustering at the arrondissement and commune lev-
els. The sampling weights use for the Benin survey are 
described in further detail in Additional file 1.
Standard ACTwatch indicators were calculated in line 
with previous outlet surveys [9, 15, 19]. Anti-malarials 
were classified as ACT, non-artemisinin therapy, and oral 
or non-oral artemisinin monotherapy. ACT were further 
classified as quality-assured ACT or non-quality assured 
ACT by matching product information to lists of WHO 
prequalified anti-malarials and Global Fund anti-malarial 
procurement lists.
Availability of any anti-malarial was calculated with all 
screened outlets as the denominator. In the public sec-
tor, the availability of specific types of anti-malarials was 
calculated using the denominator of all screened outlets 
given that anti-malarials should be available at all public 
health facilities and among CHWs. Availability of spe-
cific anti-malarial categories in the private sector was 
calculated using the total number of private-sector out-
lets stocking any anti-malarial as the denominator.
Market share was defined as the relative distribution 
of anti-malarials to individual consumers in the week 
preceding the survey. In order to allow for meaningful 
market share comparisons between products, informa-
tion about anti-malarial distribution was standardized 
to the adult equivalent treatment dose (AETD). AETD is 
the amount of active ingredient necessary to treat a 60 kg 
adult according to WHO treatment guidelines [20]. Vol-
umes distributed were calculated by converting provider 
reports on the number of anti-malarials sold in the week 
prior to the survey into AETDs. Volumes were therefore 
the number of AETDs sold or distributed by a provider in 
the seven days prior to the survey. All dosage forms were 
considered when measuring volumes to provide a com-
plete assessment of anti-malarial market share. Public 
and private-sector booster sample outlets were excluded 
from market share calculations to avoid over-estimating 
the role of the private sector.
Median private sector price per AETD was calculated 
for quality-assured ACT and other non-artemisinin ther-
apies including chloroquine, SP, and quinine. The inter-
quartile range [IQR] was calculated to demonstrate price 
dispersion. Anti-malarial price was collected in West 
African Communauté Financière Africaine (CFA) and 
converted to United States (US) dollars based on official 
exchange rates for the six-week data collection period.
Provider perceptions regarding the most effective first-
line treatment was assessed by administering questions 
to the senior most provider at all anti-malarial-stocking 
outlets. Providers were asked to describe what medicine 
they believed was the most effective treatment for treat-
ing uncomplicated malaria in a child and in an adult.
Results
A total of 7260 outlets were screened for availability of 
anti-malarials and/or malaria blood testing services. Of 
screened outlets 2966 met one of the three screening cri-
teria, including 2959 who were stocking anti-malarials 
on the day of the survey or within the past three months 
or provided malaria testing. A total of 17,669 anti-malar-
ial and 494 RDT products were audited (Additional 
file 2).
Public sector availability
Table  1 shows the availability among all screened public 
sector outlets. Availability of any anti-malarial was 95.0% 
among public health facilities and 59.4% among CHWs. 
Nine in ten public health facilities stocked quality-assured 
ACT (89.9%) and 54.8% of CHWs. Among public health 
facilities, availability of the four different package AL pack 
sizes (6, 12, 18 and 24 tablets) suitable for management of 
four different weight categories of patients (5–14; 15–24; 
25–34 and ≥35 kg) ranged from 48.8 to 65.9% (Additional 
file 3). Among CHW, 50.4% had AL for children 5–15 kg 
in stock (a package of six tablets) and availability of other 
weight/age formulations was less than 5%. SP was avail-
able in 73.9% of public health facilities and was not found 
among CHWs. Oral quinine was available in 87.7% of 
public health facilities and among 2.3% of CHWs.
Availability of malaria blood testing was 94.7% among 
public health facilities and 68.4% among CHWs. Malaria 
blood testing stocking rates were largely attributed to the 
availability of RDT.
The readiness of public-sector outlets for malaria case 
management, defined as stocking both quality-assured 
ACT and having malaria blood testing, was 89.0% among 
public health facilities and 49.7% among CHWs.
Private sector availability
Among all screened private sector outlets, availability of 
anti-malarials was as follows: 85.8%, private for-profit 
facilities; 94.6%, pharmacies; 27.5%, general retailers; and 
67.7%, itinerant drug vendors (Table 2).
Among the outlets stocking at least one anti-malarial in 
stock, 36.1% had a quality-assured ACT. This was most 
commonly available among pharmacies (90.0%) com-
pared to private for-profit facilities, general retailers, 
and itinerant drug vendors (36.4, 35.4 and 34.2%, respec-
tively). 31.3% of ACTs in the private sector were marked 
Page 7 of 15ACTwatch Group  et al. Malar J  (2017) 16:174 
Table 1 Availability of anti-malarial and malaria blood testing among all public sector outlets screened
a Includes public non-for profit sector (N = 93)
Public health facility CHW Total public  sectora
% (95% CI) % (95% CI) % (95% CI)
Availability of: N = 298 N = 145 N = 536
 Any anti-malarial 95.0 (90.3, 97.4) 59.4 (40.2, 76.1) 72.6 (58.1, 83.5)
 Quality-assured ACT 89.9 (83.9, 93.8) 54.8 (32.2, 75.7) 59.4 (43.6, 73.4)
 Quality ACT with the ‘green leaf’ logo 3.0 (0.9, 9.8) 0.6 (0.1, 4.3) 4.7 (2.0, 10.8)
 Sulfadoxine–pyrimethamine 73.9 (63.9, 81.9) 0.0 (–) 20.6 (14.9, 27.7)
 Oral quinine 87.7 (82.7, 91.3) 2.3 (0.4, 11.7) 33.2 (25.0, 42.6)
 Chloroquine 0.4 (0.1, 1.6) 0.0 (–) 1.3 (0.5, 3.5)
 Oral artemisinin monotherapy 0.0 (–) 0.0 (–) 0.0 (–)
 Artesunate injection 5.3 (1.6, 16.6) 0.0 (–) 1.3 (0.4, 4.1)
 Artemether injection 6.2 (2.1, 16.7) 0.0 (–) 5.5 (2.5, 11.8)
 Quinine injection 79.3 (69.5, 86.5) 4.5 (0.8, 22.1) 32.2 (23.9, 41.9)
Availability of: N = 298 N = 145 N = 536
 Any diagnostic test 94.7 (90.1, 97.2) 68.4 (47.3, 84.0) 69.4 (56.9, 79.6)
 Microscopy 28.7 (21.4, 37.2) 0.9 (0.1, 5.1) 8.9 (6.0, 13.0)
 RDT 94.4 (89.8, 96.9) 68.4 (47.3, 84.0) 68.3 55.8, 78.7)
Readiness for malaria case management: N = 298 N = 145 N = 536
 Quality-assured ACT and malaria testing available 89.0 (82.7, 93.2) 49.7 (28.4, 71.2) 53.7 (39.2, 67.6)
 Quality-assured ACT no malaria testing available 1.0 (0.2, 3.6) 5.1 (2.3, 11.0) 5.7 (3.1, 10.2)
Table 2 Availability of anti-malarial and malaria blood testing among the private outlets
a Total private sector includes 32 drug stores
Private for-profit facility Pharmacy General retailer Itinerant drug vendor Total private  sectora
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Among all screened outlets: N = 262 N = 176 N = 5622 N = 632 N = 6724
 Availability of any anti-malarial 85.8 (77.6, 91.3) 94.6 (76.5, 99.0) 27.5 (21.9, 34.0) 67.7 (38.8, 87.4) 33.3 (30.2, 36.7)
Among anti-malarial stocking outlets, 
availability of:
N = 222 N = 170 N = 1388 N = 468 N = 2278
 Quality-assured ACT 36.4 (23.0, 52.2) 90.0 (75.0, 96.5) 35.4 (27.9, 43.8) 34.2 (22.3, 48.4) 36.1 (27.7, 45.5)
 Quality-assured AL 35.9 (22.7, 51.6) 89.5 (74.9, 96.1) 35.1 (27.5, 43.6) 34.2 (22.3, 48.4) 35.9 (27.5, 45.3)
 Quality ACT with the ‘green leaf’ 
logo
25.0 (15.5, 37.6) 0.1 (0.0, 0.8) 33.2 (25.7, 41.7) 28.9 (17.1, 44.6) 31.3 (23.0, 41.0)
 Non quality-assured ACT 19.3 (13.3, 27.2) 100.0 (–) 12.7 (8.4, 18.9) 13.0 (7.5, 21.6) 14.8 (10.6, 20.3)
 Sulfadoxine–pyrimethamine 24.6 (16.2, 35.5) 56.6 (39.5, 72.3) 29.4 (19.8, 41.4) 68.1 (42.9, 85.8) 36.4 (22.1, 53.7)
 Oral quinine 70.5 (64.0, 76.3) 67.6 (46.7, 83.2) 34.3 (21.1, 50.5) 60.1 (36.1, 80.1) 42.5 (26.1, 60.7)
 Chloroquine 11.1 0.0 (–) 71.3 (54.7, 83.6) 38.4 (19.0, 62.4) 59.2 (39.9, 76.1)
 Other non-artemisinin 3.4 (1.3, 8.4) 15.6 (8.6, 26.6) 2.1 (1.3, 3.4) 8.6 (5.7, 12.8) 3.6 (2.1, 6.0)
 Oral artemisinin monotherapy 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–)
 Artesunate injection 1.5 (0.5, 4.3) 23.9 (14.5, 36.8) 0.0 (–) 0.0 (–) 0.5 (0.2, 0.9)
 Artemether injection 28.8 (19.9, 39.7) 70.3 (55.5, 81.8) 0.8 (0.3, 2.2) 0.0 (–) 4.1 (2.9, 5.8)
 Quinine injection 82.7 (75.7, 88.0) 30.4 (19.0, 44.9) 1.7 (0.8, 3.7) 0.0 (–) 8.7 (6.4, 11.8)
Among outlets stocking anti-malarials 
today or within the past 3 months, 
availability of:
N = 233 N = 170 N = 1530 N = 496 N = 2459
Any diagnostic test 39.2 (30.6, 48.5) 5.0 (1.4, 16.0) 0.1 (0.0, 0.3) 0.0 (–) 3.3 (2.3, 4.7)
Malaria microscopy 17.9 (8.7, 33.2) 0.0 (–) 0.0 (–) 0.0 (–) 1.5 (0.8, 2.8)
RDT 26.1 (16.8, 38.3) 5.0 (1.4, 16.0) 0.1 (0.0, 0.3) 0.0 (–) 2.2 (1.3, 3.8)
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with the ‘green leaf ’ logo. Adult quality-assured ACT was 
available in 24.6% of private-sector outlets. The three 
child formulations were available in less than 15% of the 
private sector (Additional file 4).
Chloroquine was available in 59.2% of the private sec-
tor followed by oral quinine (42.5%) and SP (36.4%), 
though there were several differences across outlet types. 
For example, chloroquine was most commonly stocked 
by general retailers (71.3%) while SP was most commonly 
available among itinerant drug vendors (68.1%) and oral 
quinine was available in 70.5% private for-profit facilities.
Anti-malarial market share
Figure  1  shows the market share of different categories 
of anti-malarials sold or distributed in the 7 days prior to 
the survey. A total of 25,427 anti-malarial AETDs were 
reportedly distributed in seven days before the survey.
21.5% of the anti-malarial market share was distrib-
uted by the public sector, which was comprised mostly 
of quality-assured ACT without the ‘green leaf ’ logo 
(9.9% of total market share) and of SP (6.5% of the total 
market).
Almost 80% of the anti-malarials distributed were 
through the private sector (78.5%). Quality-assured 
ACT with the ‘green leaf ’ logo comprised 15.6% of the 
total anti-malarial market share, followed by non-quality 
assured ACT (without the logo), which comprised 14.3%. 
SP made up the largest market share of non-artemisinin 
































































Quality-assured ACT without green leaf logo
Quality-assured ACT with green leaf logo
Fig. 1 Anti-malarial market share
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Overall, general retailers dominated the anti-malarial 
market, accounting for 47.6% of the total market share in 
Benin, and these providers distributed most of the qual-
ity-assured ACT with the ‘green leaf ’ logo (13.4% of total 
market share), SP (14.7%), and chloroquine (12.0%).
Malaria diagnostic market share
Figure  2  shows the diagnostic market share of different 
types of malaria tests administered in the seven  days 
prior to the survey. A total of 6712 malaria test units, 
either microscopy or RDT, were reportedly distributed or 
used in the seven days prior the outlet survey.
Most of the malaria testing was performed through 
the public sector, which accounted for 82.2% of the total 
diagnostic testing market share. Microscopy testing was 
rare across both the public and the private sector, 14.8 
and 6.8% respectively.
Within the private sector, malaria blood testing market 
share was dominated entirely by private for-profit health 
facilities since none of the other private sector out-
lets reportedly distributed or sold malaria testing in the 
seven days before the survey.
Price
Private sector price of AETD quality-assured ACT 
($1.35, inter quartile range [IQR] $1.0, $2.02) was 
three times more expensive than SP ($0.42, IQR $0.34, 
$0.51) or chloroquine ($0.41, IQR $0.41–$0.42). The 
price of AETD quinine was $3.54 (IQR $2.83–$4.25)—
2.6 times more expensive than one quality-assured 
ACT.
Provider perceptions of most effective treatment
When providers were asked what they perceived to be 
the most effective anti-malarial for the treatment of 
uncomplicated malaria in children or adults, results 
from the public sector illustrate that most providers 
cited an ACT. Among public health facility providers, 
94.6 and 96.4% perceived ACTs was the most effective 
treatment in adults and in children respectively (Figs. 3, 
4). Specific to the question regarding the most effective 
treatment for adults, 37.2% of CHWs responded that 
they did not know, while 59.8% perceived ACT as the 
most effective for an adult and 91.8% of them perceived 
an ACT as the most effective for children.
In the private sector, 62.7% of private for-profit and 93% 
of pharmacy providers cited an ACT as the most effec-
tive treatment for adults, and 73.4 and 94.9% respectively 
cited this as most effective for children. Non-artemisinin 
therapies, typically chloroquine and quinine, were cited 
as most effective treatment among general retailers (chlo-
roquine, children: 24.8%; adults: 34.4%; quinine, children: 
15.4%; adults: 18.3%) and itinerant drug vendors (chloro-
quine, children: 17.6%; adults: 29.8%; quinine, children: 
43.1%; adults: 30.5%). SP was commonly cited as the 
most effective treatment for adults by itinerant drug ven-
dors (29.8%).
Discussion
The 2016 outlet survey provided a complete picture of the 
malaria testing and treatment landscape across the public 
and private sectors, providing information on availabil-

















































Fig. 2 Diagnostic market share
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findings point to recommendations for improving pri-
vate-sector malaria case management in Benin.
Public sector readiness for appropriate malaria case 
management
Public health facilities showed high readiness for appropri-
ate case management in Benin. There was nearly universal 
coverage of quality-assured ACT treatment and malaria 
blood testing in these facilities. These findings reflect 
national strategies that have been in place since 2011, 
which stipulate confirmatory testing prior to treatment 
for all ages and at all levels of care [6]. The current levels 
of readiness reflect a substantial increase from diagnostic 
availability measured in 2011, where just over half of the 
public health facilities had malaria testing available (56.8%) 
[17], illustrating that national policy has been successful in 
increasing access to confirmatory testing in this sector.
Three-quarters of public health facilities had SP avail-
able for IPTp treatment, reflecting an increase over 
time, from 17.2% in 2011 and 44.7% in 2014. This sug-
gests substantial progress has been made with regards to 
the scale-up of SP for IPTp [17, 18]. This is in-line with 
recent national strategies to increase access to SP, includ-
ing changes to the dosing regimen, and efforts to provide 
malaria services free of charge to pregnant women [6]. 
Availability of oral quinine, recommended for the treat-
ment of uncomplicated malaria in pregnancy during the 
first trimester, was also high, with over 85% of public 
health facilities stocking this medicine. These findings 
illustrate overall readiness among public health facilities 
to manage malaria in pregnant women.
According to the 2015 national guidelines, inject-
able quinine followed by oral quinine are still the rec-
ommended treatment for severe malaria, which could 
explain the high levels of quinine availability in public 
health facilities. However, it is possible that quinine is 
being used for uncomplicated malaria given it is widely 
available throughout all types of public health facili-
ties. Quinine should only be administered at hospitals, 
which would be equipped to manage patients with severe 
malaria. Furthermore, while a full course of quinine tab-
lets are indicated for treatment of severe malaria, this 
should only be administered after a primary treatment 
with injectable quinine. However, market share data illus-
trate that oral quinine comprises one in every fifth anti-
malarial distributed in the public sector, while quinine 
injection is negligible, suggesting that oral quinine may 
be routinely administered for uncomplicated malaria. 
Indeed, a recent household study in southern Benin 
found quinine was the second most used anti-malarial 
for self-medication (after ACT) suggesting that efforts 
are needed to ensure the appropriate administration of 
this anti-malarial [21]. Despite the updated WHO stand-
ards, artesunate availability remains low (5.3%). Efforts 
are currently underway to identify the barriers to increas-
ing injectable artesunate use for severe malaria treatment 
in Benin [6].
Since 2014, the reach of the public sector has been 
extended to the community-level through the training 
and equipping of CHWs with malaria case management 
skills and supplies (AL and RDT). Since then, several 
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Fig. 3 Providers’ perceptions of the most effective treatment for an uncomplicated malaria in a child
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and coordination of these providers [6]. The results from 
this survey illustrate how more than half of the CHWs 
had anti-malarials in stock, namely quality-assured ACT, 
and almost 70% had RDTs. The availability findings also 
reflect promising changes from earlier survey rounds 
where availability of ACT in 2011 was less than 50% and 
the availability of RDT was negligible (<5%). Further-
more, most CHWs perceived ACT to be the most effec-
tive treatment for uncomplicated malaria in adults and 
children. These findings point to the success of a national 
level campaign to scale-up, train, and supply CHWs to 
provide ACT and blood testing services. Key areas to 
address may be improving CHW awareness of the most 
effective anti-malarial for adults given 40% did not know 
what this was, and to maintain supply of RDTs as a means 
to increase access to confirmatory testing.
Role of the private sector in malaria case management
Results from the study confirmed the dominant role of 
the private sector across Benin, where almost 80% of all 
anti-malarials passed through this sector, mainly through 
general retailers—which accounted for almost half of 
the anti-malarial market share in 2016 (47.6%) [17, 18]. 
Of the 5600 general retail outlets that were screened for 
anti-malarials, over one in four had anti-malarials in 
stock, reflecting a three-fold increase from previous sur-
veys. General retailers as a source of anti-malarial treat-
ment have also been documented in other countries, 
including Madagascar, Myanmar, and Cambodia [22–24], 
and were also a common source of treatment in Benin as 
evidenced in a population based survey [25]. The results 
also point to the importance of itinerant drug vendors, 
of which over half of those surveyed had anti-malarials 
available, and comprised around one tenth of the anti-
malarial market share. Trend data also illustrate how the 
combined anti-malarial market share of general retail-
ers and itinerant drug vendors, subsequently referred to 
as the ‘informal’ private sector, has increased over time 
from 30.9% in 2011, 40.1% in 2014, to 56.8% in 2016 [17, 
18], illustrating the increasing relevancy of these outlets 
in the delivery of anti-malarial treatment. It is unclear 
why an increase in the informal market composition has 
been observed. Given there is little regulation of the pri-
vate sector in Benin, this growth of the informal sector 
market composition may reflect a natural evolution of the 
market to meet consumer demand for anti-malarials, and 
perhaps these outlets are more accessible to patients. In 
absence of regulation, general retailers and itinerant drug 
vendors have perhaps responded to consumer demand by 
stocking anti-malarials in addition to other products.
Given a large portion of the private-sector case man-
agement is being channeled through these informal out-
lets, there may be several opportunities to strengthen 
the malaria case management services provided by these 
vendors. There are examples in the literature of innova-
tive strategies that have focused on general retailers and 
itinerant drug vendors to improve access to quality-
assured ACT [24]. There is also a growing body of sup-
port for itinerant drug vendors as a means to improve 
home-based management of malaria [26, 27], and these 
mobile providers have been cited as a useful means to 
improve the provision of care for malaria [28]. In Benin, 
there is also documentation of ‘associations’ of drug ven-
dors, which operate within traditional markets and per-
form quasi-regulatory functions [11]. The quasi-formal 
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Fig. 4 Providers’ perceptions of the most effective treatment for an uncomplicated malaria in an adult
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accreditation programmes as a means to further regu-
late, supervise, and engage with the private sector in 
both ACT and RDT distribution. Such strategies, done 
in collaboration with the public sector, may help to com-
plement rather than compete with the existing CHW 
programme. Considering the informal sector in the 
accreditation process may be an important strategy to 
accelerate coverage of appropriate case management in 
Benin.
Readiness of the private sector in malaria case 
management
The private sector was generally less well-equipped to test 
and appropriately treat malaria infections as compared 
with the public sector. Only one-third of private-sector 
outlets were stocking quality-assured ACT. Non-arte-
misinin therapies were more commonly available and dis-
tributed. Availability of malaria testing was also negligible 
and consistent with these findings, most malaria tests 
were administered by the public sector, which comprised 
over 80% of the diagnostic market share. Given most pri-
vate-sector outlets were not stocking malaria tests sug-
gests that presumptive treatment is widespread.
Availability and market share of ACT
While the AMFm or subsequent CPM programme was 
not implemented in Benin, most of the quality-assured 
ACT reportedly distributed in the private sector had the 
AMFm ‘green leaf ’ logo. This indicates leakage of anti-
malarials’ from other countries and suggests that anti-
malarials are being illegally traded into non-subsidized 
private markets.
The widespread availability and distribution of qual-
ity-assured ACT with the logo is perhaps not surprising 
considering Benin’s supply chain [11]. The domestic anti-
malarial market in Benin is relatively small, with few local 
manufacturers, so the country’s supply relies heavily on 
imports. Many of the anti-malarial supplies are obtained 
from more developed pharmaceutical markets in sur-
rounding countries, most notably Nigeria, and imported 
largely though the informal sector. Thus, it is quite likely 
that products with the ‘green leaf ’ logo—a marker of the 
subsidized CPM ACT—have leaked into Benin’s private-
sector outlets through neighbouring Nigeria. In fact, 
prior to the AMFm, the importation of medicines illegally 
from Nigeria was noted as commonplace, with vendors 
citing ease of accessing cheap suppliers in Lagos as a key 
reason for the illegal import [11]. The widespread uptake 
of this illegally imported ACT speaks to the need for a 
national level programme targeting the private sector 
with subsidized quality-assured ACT to align the private-
sector outlets with national treatment guidelines, as well 
as a need to strengthen border control and regulation.
Availability and distribution of other non-quality 
assured ACT was also high, comprising 14.3% of the anti-
malarial market and reflecting a slight increase from ear-
lier survey rounds [16, 17]. This is of concern given that 
non-quality assured ACT medicines have not received 
pre-qualification, meaning that these medicines have 
not necessarily been manufactured according to qual-
ity standards yielding safe and efficacious medicines. 
Moreover, non quality-assured ACT have an increased 
likelihood of being poor quality as evidenced by studies 
that have tested the pharmacological properties of the 
medicines [29]. The widespread presence of non-quality 
assured ACT is of concern given its presence on the mar-
ket and use poses a threat to appropriate and effective 
malaria case management.
Availability of different AL formulations
While the strength of all first-line AL tablets for treat-
ment of uncomplicated malaria is indeed the same, the 
implementation of the AL policy includes delivery of four 
different AL pack sizes (6, 12, 18 and 24 tablets) suitable 
for management of four different weight categories of 
patients (5–14; 15–24; 25–34 and ≥35 kg). In the private 
sector, as well as the public sector, availability of the dif-
ferent weight categories was relatively poor. For example, 
in the private sector, only 11.4% of the private for-profit 
facilities and  58.6% of pharmacies had AL treatments for 
children under 5.
Maintaining a consistent supply of age/weight appro-
priate commodities will be key to ensure that ACT 
commodities are administered according to the rec-
ommended age and weight band of each patient and to 
prevent medicine packages from being cut or tampered 
with. This is particularly important given evidence that 
AL treatment is up to six times more likely to be pre-
scribed if the weight specific pack is in stock [30]. While 
several strategies are underway to better manage the sup-
ply and procurement of malaria commodities to avoid 
stock-outs, this has not been fully implemented. Tem-
porary options may be to instruct providers to adminis-
ter AL even if adequate AL pack sizes are not in stock. 
However, evidence suggests that this practice may com-
promise high levels of patients’ adherence to AL [31] and 
incorrect dosing [32, 33]. If adequate availability of first-
line ACT treatments cannot be ensured, alternative AL 
preparations that do not depend on separate packaging, 
could also be considered [30].
Availability and use of non‑artemisinin therapies
Over a decade after the change in first-line treatment 
for uncomplicated malaria, non-artemisinin therapies, 
including SP, oral quinine, and chloroquine, accounted 
for the majority (57.7%) of the market share in the private 
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sector. SP made up over half of the non-artemisinin ther-
apies reportedly distributed. While most of the SP distri-
bution was through itinerant drug vendors and general 
retailers, SP was also commonly distributed by pharma-
cies. The widespread distribution of this medicine implies 
that it is being used for malaria case management rather 
than exclusively for IPTp as recommended. Widespread 
availability and distribution of oral quinine, particularly 
among general retailers and itinerant drug vendors, also 
indicates this is being used for the treatment of uncom-
plicated malaria.
Widespread distribution of non-artemisinin thera-
pies in Benin might be explained by a number of factors. 
This may in part be attributed to price, given that SP and 
chloroquine were three times less expensive than quality-
assured ACT. Alternatively, access may also be an impor-
tant factor. Non artemisinin therapies were more widely 
available than quality-assured ACT—particularly among 
general retailers where most anti-malarials were distrib-
uted. Another reason may be around provider percep-
tions of the most effective treatment for uncomplicated 
malaria. In 2016, most of the itinerant drug vendors and 
general retailers perceived non-artemisinin therapies (SP, 
chloroquine, or quinine) as the most effective treatment 
for uncomplicated malaria.
To improve private-sector case management, removal 
of non-artemisinin therapies from the market is para-
mount and new strategies are necessary to curtail their 
consumption and promote the use of quality-assured 
ACT and RDT in the private sector. Several programmes 
have been implemented across sub-Saharan Africa to 
improve private sector readiness for appropriate malaria 
case management that could be relevant in the Benin 
context. A similar nation-wide subsidy to that of the 
AMFm may be an immediate means to overcome ACT 
access and affordability issues for this treatment, as evi-
dence by the pilot initiative [34, 35]. Once barriers related 
to access of quality-assured ACT have been addressed, 
mass-media behaviour change campaigns may be a par-
ticularly effective strategy in Benin to increase awareness 
of the first-line treatment and to promote demand for 
the quality ACT product. Several studies have demon-
strated how consumer demand is associated with treat-
ment and how patient preferences influence provider 
dispensing behaviour [36–39]. Specifically in Benin, qual-
itative research found that provider stocking decisions 
were overwhelmingly driven by patient demand, which 
led some outlets not to stock ACT [11]. Furthermore, 
provider training and supervision may also be merited 
to improve the quality of case management practices, 
including accreditation of outlets as previously discussed. 
Such multi-pronged strategies are likely to improve 
malaria case management and can improve private sector 
readiness and performance, as has been demonstrated in 
other contexts [12].
Availability of oral artemisinin monotherapy
Oral artemisinin monotherapy poses a serious threat to 
the continued efficacy of artemisinins, and as such this 
anti-malarial was banned in Benin in 2008. In 2016, no 
oral artemisinin monotherapy was detected in the mar-
ket. This is of promise given ACTwatch outlet survey 
findings from neighboring Nigeria which show that avail-
ability of oral artemisinin monotherapy in the private 
sector has increased from 24.6% in 2013 to 37.3% in 2015 
[40]. Given that Nigeria appears to be a source of supply 
of anti-malarials to Benin’s private sector market, it is 
important that availability of oral artemisinin monother-
apy in the market is routinely monitored. Mystery clients 
to detect unwanted or banned medicines may be a useful 
method to do this [41].
Limitations
The ACTwatch outlet survey design has limitations that 
have been documented and reported [9, 15, 19]. One 
point to mention is that while anti-malarial audits were 
carried out by researchers, sales volumes were reported 
by the provider and these responses were open to positive 
response bias. The pros and cons of using self-reported 
sales volumes, versus other methods to capture market 
share such as sale inventory audits or exit interviewers, 
suggests that there are advantages and disadvantages of 
different methods but no method is gold standard and 
each has its own limitations [42].
Other specific limitations to Benin’s outlet survey 
include the use of two different forms of data collection 
(electronic and paper questionnaires). While electronic 
data collection has the advantage of recording the data 
instantly with all the relevant checks and skip patterns 
built into the programme, it may have had an impact on 
respondents’ fear that they were being recorded or inves-
tigated. In addition, some itinerant vendors could have 
been missed during the survey given these vendors may 
work late at night and, for security reasons, interviewers 
only worked during the day and early evening.
Conclusions
The public sector in Benin is typically well equipped to 
test and appropriately treat malaria according to national 
treatment guidelines. However, the private sector is 
responsible for most of the anti-malarial distribution, 
typically through general retailers, and this channel most 
commonly distributes non-artemisinin therapies. There 
is also evidence of leakage of subsidized ACT from neigh-
bouring countries. A national strategy to scale up access 
to first-line, quality-assured, subsidized treatment as a 
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means to improve coverage and quality of malaria case 
management services is needed. Strategies to increase 
coverage of malaria commodities should be supported 
by interventions to address provider perceptions, as well 
as consumer behaviours, and innovative approaches to 
either engage or regulate Benin’s informal private sector 
are needed.
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